Oliver Schnell, Arnav Agarwal, Michel Azizi, Dennis Ballwieser, Katharine Barnard-Kelly, Tadej Battelino, Dennis Ballwieser, Matthias Blüher, Elisabetta Bugianesi, Ana Cebrian, Antonio Ceriello, Pratik Choudhary, Thomas Danne, Colin M Dayan, Stefano Del Prato, Robert H Eckel, Paola Fioretto, Timothy Garvey, Jennifer B Green, Hiddo J L Heerspink, Rury R Holman, Baruch Itzhak, Stephan Jacob, Pardeep S Jhund, Linong Ji, Parminder K Judge, Kamlesh Khunti, Marko Korenjak, Andrew J Krentz, Ekaterini Lambrinou, Peter Libby, Julia K Mader, Johannes F E Mann, Nikolaus Marx, Chantal Mathieu, John J V McMurray, Dirk Müller-Wieland, Nikolaos Papanas, Dipesh C Patel, Andreas F H Pfeiffer, Susanne Reger-Tan, Helena W Rodbard, Giuseppe M C Rosano, Banshi Saboo, Naoki Sato, Scott D Solomon, Eberhard Standl, Frank Tacke, Pinar Topsever, Christoph Wanner, Sean Wharton, Veronika Young
{"title":"CVOT峰会报告2025：沿着心血管-肾脏-代谢疾病连续体的进展","authors":"Oliver Schnell, Arnav Agarwal, Michel Azizi, Dennis Ballwieser, Katharine Barnard-Kelly, Tadej Battelino, Dennis Ballwieser, Matthias Blüher, Elisabetta Bugianesi, Ana Cebrian, Antonio Ceriello, Pratik Choudhary, Thomas Danne, Colin M Dayan, Stefano Del Prato, Robert H Eckel, Paola Fioretto, Timothy Garvey, Jennifer B Green, Hiddo J L Heerspink, Rury R Holman, Baruch Itzhak, Stephan Jacob, Pardeep S Jhund, Linong Ji, Parminder K Judge, Kamlesh Khunti, Marko Korenjak, Andrew J Krentz, Ekaterini Lambrinou, Peter Libby, Julia K Mader, Johannes F E Mann, Nikolaus Marx, Chantal Mathieu, John J V McMurray, Dirk Müller-Wieland, Nikolaos Papanas, Dipesh C Patel, Andreas F H Pfeiffer, Susanne Reger-Tan, Helena W Rodbard, Giuseppe M C Rosano, Banshi Saboo, Naoki Sato, Scott D Solomon, Eberhard Standl, Frank Tacke, Pinar Topsever, Christoph Wanner, Sean Wharton, Veronika Young","doi":"10.1186/s12933-026-03140-0","DOIUrl":null,"url":null,"abstract":"<p><p>The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emphasis on the importance of early detection and innovative treatment strategies. The 12th Cardiovascular Outcome Trial Summit will be held virtually on 19-20 November 2026 ( http://www.cvot.org ).</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":10.6000,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147710/pdf/","citationCount":"0","resultStr":"{\"title\":\"CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.\",\"authors\":\"Oliver Schnell, Arnav Agarwal, Michel Azizi, Dennis Ballwieser, Katharine Barnard-Kelly, Tadej Battelino, Dennis Ballwieser, Matthias Blüher, Elisabetta Bugianesi, Ana Cebrian, Antonio Ceriello, Pratik Choudhary, Thomas Danne, Colin M Dayan, Stefano Del Prato, Robert H Eckel, Paola Fioretto, Timothy Garvey, Jennifer B Green, Hiddo J L Heerspink, Rury R Holman, Baruch Itzhak, Stephan Jacob, Pardeep S Jhund, Linong Ji, Parminder K Judge, Kamlesh Khunti, Marko Korenjak, Andrew J Krentz, Ekaterini Lambrinou, Peter Libby, Julia K Mader, Johannes F E Mann, Nikolaus Marx, Chantal Mathieu, John J V McMurray, Dirk Müller-Wieland, Nikolaos Papanas, Dipesh C Patel, Andreas F H Pfeiffer, Susanne Reger-Tan, Helena W Rodbard, Giuseppe M C Rosano, Banshi Saboo, Naoki Sato, Scott D Solomon, Eberhard Standl, Frank Tacke, Pinar Topsever, Christoph Wanner, Sean Wharton, Veronika Young\",\"doi\":\"10.1186/s12933-026-03140-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emphasis on the importance of early detection and innovative treatment strategies. The 12th Cardiovascular Outcome Trial Summit will be held virtually on 19-20 November 2026 ( http://www.cvot.org ).</p>\",\"PeriodicalId\":9374,\"journal\":{\"name\":\"Cardiovascular Diabetology\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":10.6000,\"publicationDate\":\"2026-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147710/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Diabetology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12933-026-03140-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Diabetology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12933-026-03140-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.
The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emphasis on the importance of early detection and innovative treatment strategies. The 12th Cardiovascular Outcome Trial Summit will be held virtually on 19-20 November 2026 ( http://www.cvot.org ).
期刊介绍：
Cardiovascular Diabetology is a journal that welcomes manuscripts exploring various aspects of the relationship between diabetes, cardiovascular health, and the metabolic syndrome. We invite submissions related to clinical studies, genetic investigations, experimental research, pharmacological studies, epidemiological analyses, and molecular biology research in this field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
